Last reviewed · How we verify
PEG-Asparaginase
PEG-Asparaginase is a Small molecule drug developed by Dana-Farber Cancer Institute. It is currently FDA-approved. Also known as: Oncaspar, Pegaspargase, Polyethylene Glycol Conjugated L-asparaginase-H, Oncaspar®.
PEG-Asparaginase is an enzyme used in the treatment of various types of leukemia, including T-cell Childhood Acute Lymphoblastic Leukemia and Acute Lymphoblastic Leukemia. It works by hydrolyzing the amino acid asparagine, which is necessary for the growth of certain cancer cells.
At a glance
| Generic name | PEG-Asparaginase |
|---|---|
| Also known as | Oncaspar, Pegaspargase, Polyethylene Glycol Conjugated L-asparaginase-H, Oncaspar®, PEG-L-asparaginase |
| Sponsor | Dana-Farber Cancer Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma (PHASE2)
- A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL (PHASE2)
- Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (PHASE3)
- LBL-2016 for Children or Adolescents in China (PHASE3)
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PEG-Asparaginase CI brief — competitive landscape report
- PEG-Asparaginase updates RSS · CI watch RSS
- Dana-Farber Cancer Institute portfolio CI
Frequently asked questions about PEG-Asparaginase
What is PEG-Asparaginase?
Who makes PEG-Asparaginase?
Is PEG-Asparaginase also known as anything else?
What development phase is PEG-Asparaginase in?
Related
- Manufacturer: Dana-Farber Cancer Institute — full pipeline
- Also known as: Oncaspar, Pegaspargase, Polyethylene Glycol Conjugated L-asparaginase-H, Oncaspar®, PEG-L-asparaginase
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing